Wheaton acquired most operations of MicroLiter Analytical Supplies for an undisclosed price today. The deal expands Wheaton’s product line and support services for the global high-performance liquid chromatography (HPLC) market.

“We’re looking forward to a synergistic relationship in which we can better support scientists and researchers, through efficiencies and product line expansion,” Wayne Brinster, Wheaton’s president, said in a statement.

Brinster joined Wheaton in October from Synthon Pharmaceuticals, where he served as vp and general manager. He succeeded Stephen R, Drozdow, who held the position since 1996 and remains the company’s CEO. At the time Brinster was appointed president, Wheaton said it would maintain its business focus on supporting laboratory research, and packaging for diagnostics and specialty pharmaceutical markets.

The deal is Wheaton’s second acquisition of select business product lines in six months. Back in July, Wheaton acquired the dual membrane, cell culture flasks of CellLINE™ from its owner, Wilson Wolf Manufacturing. Wheaton also entered into a long- term strategic partnership with Wilson Wolf Manufacturing  for further product development in high density cell culture devices for producing concentrated, cell secreted products.

Headquartered in Suwanee, GA, MicroLiter was founded in 1996 and focuses on supplying precleaned chromatography sample vials and accessories for use with autosamplers. Its product lines include pre-cleaned, sample containment products processed in Class 10,000 cleanroom facilities, as well as 12×32 mm glass autosampler vials, inserts, septa and closures, and the MicroLiter Plate Sampling System, which brings a 96-well, multi-array sample handling format for chromatography autosamplers.

Wheaton said it will support continued product development of, and service improvements to, the acquired MicroLiter business lines, by tapping into its own supply chain expertise and sales support.

Not included in the acquisition were MicroLiter’s Instrument Top Sample Preparation products and patents, which will be retained by the acquired company’s previous management. That portion of MicroLiter’s business did not fit Wheaton’s business model, the company said.

Previous articleRNA Splicing Provides Species with New Alternatives
Next articleMS Research Gets $1.4M Boost